Table 1.

Patient characteristics in 6 patient cohorts

Cohort 1 (N = 229)Cohort 2 (N = 168)Cohort 3 (N = 506)Cohort 4 (N = 125)Cohort 5 (N = 80)Cohort 6 (N = 195)
Gender
 Male123 (53.7%)90 (53.6%)279 (55.1%)63 (50.4%)44 (55.0%)103 (52.8%)
 Female106 (46.3%)78 (46.4%)227 (44.9%)62 (49.6%)36 (45.0%)92 (47.2%)
Age, years
 Median (range)67 (26–92)67 (22–97)68 (22–97)68 (23–87)60.5 (25–89)69 (35–90)
Location
 Right colon102 (44.5%)57 (33.9%)206 (40.7%)50 (40.0%)NA67 (34.4%)
 Left colon95 (41.5%)72 (42.9%)300 (59.3%)65 (52.0%)NA65 (33.3%)
 Rectum30 (13.1%)0 (0.0%)0 (0.0%)10 (8.0%)NA62 (31.8%)
 Unknown2 (0.9%)39 (23.2%)0 (0.0%)0 (0.0%)NA1 (0.5%)
Stage
 I44 (19.2%)4 (2.4%)37 (7.3%)28 (22.4%)0 (0.0%)43 (22.1%)
 II94 (41.0%)88 (52.4%)264 (52.2%)48 (38.4%)0 (0.0%)72 (36.9%)
 III91 (39.7%)76 (45.2%)205 (40.5%)49 (39.2%)0 (0.0%)49 (25.1%)
 IV0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)80 (100.0%)29 (14.9%)
 Unknown0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)2 (1.0%)
Adjuvant chemotherapy
 Yes87 (38.0%)23 (13.7%)203 (40.1%)NANANA
 No142 (62.0%)15 (8.9%)301 (59.5%)NANANA
 Unknown0 (0.0%)130 (77.4%)2 (0.4%)NANANA
KRAS status
 WTNANA297 (58.7%)NA43 (53.8%)115 (59.0%)
 MutantNANA188 (37.2%)NA27 (33.8%)80 (41.0%)
 UnknownNANA21 (4.2%)NA10 (12.5%)0 (0.0%)
MSI status
 pMMRNANA388 (76.7%)87 (69.6%)NA172 (88.2%)
 dMMRNANA73 (14.4%)28 (22.4%)NA23 (11.8%)
 UnknownNANA45 (8.9%)10 (8.0%)NA0 (0.0%)
YAP1 signature
 IYCC163 (71.2%)102 (60.7%)366 (72.3%)92 (73.6%)57 (71.3%)166 (85.1%)
 AYCC66 (28.8%)66 (39.3%)140 (27.7%)33 (26.4%)23 (28.8%)29 (14.9%)

Abbreviations: MSI, microsatellite instability; pMMR, proficient mismatch repair; dMMR, deficient mismatch repair; NA, not available.